Synthesis of cyclic imide containing peptide products

Information

  • Patent Grant
  • 10450343
  • Patent Number
    10,450,343
  • Date Filed
    Wednesday, March 19, 2014
    10 years ago
  • Date Issued
    Tuesday, October 22, 2019
    5 years ago
Abstract
The present invention relates to a method of synthesizing a peptide product comprising at least one cyclic imide group. Further, the invention relates to a peptide product comprising at least one cyclic imide group, which is substantially free from degradation products. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of a GLP-1 agonist like exendin peptides.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/EP2014/055511, filed Mar. 19, 2014, which claims priority to the European Patent Application No. 13160380.5, filed on Mar. 21, 2013.


SUMMARY OF DISCLOSURE

The present invention relates to a method of synthesizing a peptide product comprising at least one cyclic imide group. Further, the invention relates to a peptide product comprising at least one cyclic imide group, which is substantially free from degradation products. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of GLP-1 agonists like exendin peptides.


Using well-known recombinant DNA and chemical solid phase synthesis processes, several proteins and peptides have been synthesized for pharmaceutical use. The production of these proteins and peptides, however, often leads to a multiplicity of undesired synthesis by-products. This is especially the case when they are produced by solid phase synthesis. With an increase in length of the peptide/protein, leading to an increase in the synthesis steps, these by-products may be present in 50 to 70% of the crude product.


The by-products may include peptide products containing cyclic imide groups, e.g. aspartimides or glutarimides. Such cyclic imide groups are generated during or after the solid phase synthesis, e.g. when removing a peptide from the solid phase carrier or when formulating or storing a peptide composition (Geiger & Clarke, J. Biol. Chem. 262 (1987), 785-794; Hekman et al., J Pharm. Biomed. Anal. 20 (1999), 763-772; Lindner & Helliger, Exp. Gerontol. 36 (2001), 1551-1563; Aswad et al., J. Pharm. Biomed. Anal. 21 (2000), 1129-1136; Ritz-Timme & Collins, Ageing Res. Rev. 1 (2002), 43-59; Mergler et al., J. Pept. Sci. 9 (2003), 36-46; Mergler et al., J. Pept. Sci. 9 (2003), 518-526: Mergler et al., J. Pept. Sci. 11 (2005), 650-657; Cebrian et al., J. Pept. Res. 62 (2003), 238-244; De Boni et al., J. Chrom. A. 1022 (2004), 95-102; and Houchin et al., J. Contr. Release 112 (2006), 111-119).


A targeted synthesis of peptide products containing cyclic imide groups is not known. In the past, aspartimides or glutarimides have been generated by “forced degradation” procedures, wherein a peptide comprising the amino acids Asp or Asn is subjected to degradation conditions, e.g. stirring at pH 4 or pH 8 for one to two days, optionally at an elevated temperature of about 40 to about 50° C. These methods, however, have the disadvantage that in addition to the desired products, numerous other degradation products are obtained. Particularly, the cyclic imide group may be subject to further reactions, e.g. racemisation, formation of an isoaspartate peptide, conversion from Asn to Asp, opening of the aspartimide by nucleophilic reagents, peptide bond cleavage, etc. Thus, after performing a forced degradation, it is often difficult to purify the desired cyclic imide product from a complex mixture of peptidic compounds.


In order to overcome these difficulties occurring in the manufacture and purification of the cyclic imide peptide products, the present inventors have developed a targeted synthesis for cyclic imide containing peptides.


This method is shown exemplarily for the peptide Lixisenatide (AVE0010), a GLP-1 agonist having a length of 44 amino acids long. The amino acid sequence of Lixisenatide is shown in SEQ ID NO:1:









H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-





W-L-K-N-G-G-P-S-S-G-A-P-P-S-K-K-K-K-K-K-NH2






Lixisenatide is produced by a chemical solid phase synthesis process.


Aspartimides may be formed from peptide sequences -Asn-X- or -Asp-X-, wherein X denotes a C-terminally adjacent amino acid residue. In the former case, the cyclisation involves removal of ammonia (NH3) and in the latter case, removal of water (H2O). In FIG. 1, the formation of aspartimides in AVE0010, namely on position -Asn(28)-Gly(29)- and Asp(9)-Leu(10) is illustrated. The resulting products are designated [Asp(9)-H2O]-AVE0010 and [Asn(28)-NH3]-AVE0010, respectively. In principle, the same reaction results in the formation of glutarimides from the amino acids Gln or Glu.


The present inventors have now found that a targeted synthesis of cyclic imide groups is possible when using an amino acid building block with an unprotected COOH or CONH2 side chain, e.g. Asp, Asn or Glu, Gln in the coupling step during peptide synthesis at predetermined positions where formation of cyclic imide groups is desired. At other positions where formation of cyclic imide groups is not desired, amino acid building blocks with a protected COOH or CONH2 side chain may be used in the synthesis. By increasing the coupling time and repeated addition of coupling reagents, the cyclic imide groups may be obtained in nearly quantitative yield. Thus, the present invention allows selective formation of cyclic imide groups at predetermined positions of a peptide sequence without affecting other positions of the peptide sequence potentially susceptible to cyclic imide group formation.


In FIG. 2, formation of an aspartimide group is shown. An amino-protected (e.g. by Fmoc) protected Asp building block with an unprotected carboxy side chain is added to a carrier resin-bound peptide derivative with a free amino group in the presence of coupling reagents. Formation of the aspartimide group is favoured by increasing the coupling time to ≥1 day and repeated adding of coupling reagents. The other steps of peptide synthesis, i.e. previous and/or subsequent steps, may be carried out under standard conditions. It should be avoided, however, to use piperidine for the cleavage of the Fmoc protection group, because this may lead to an opening of the aspartimide ring.


The method of the present invention allows a targeted synthesis of cyclic imide peptide products in high yield and purity. These peptide products may e.g. be used as reference materials for the quality control of pharmaceutical peptide products such as lixisenatide.


A subject-matter of the present invention is a method of synthesizing a peptide product comprising at least one cyclic imide group of formula (I) or a salt or solvate thereof:




embedded image


  • wherein

  • R1 is a bridge (or biradical) of one or two atoms lengths,

  • R2 is an amino acid side chain,

  • * denotes an asymmetric C atom, preferably in the L-configuration, and

  • (*) denotes an optionally asymmetric C atom, preferably in the L-configuration,

  • comprising the steps:

  • (a) coupling a synthesis building block of formula (II):





embedded image


  • wherein
    • X is an amino protecting group,
    • Y is an unprotected carboxy or carboxamido group,
    • Z is a carboxy group, and
    • * denotes an asymmetric C atom, preferably in the L-configuration, to a peptide product of formula (III)





embedded image


  • wherein
    • R2′ is an optionally protected amino acid side chain,
    • R3 is a peptidic residue, preferably bound to a solid phase carrier, and
    • (*) denotes an optionally asymmetric C atom, preferably in the L-configuration, under conditions wherein the cyclic imide group of formula (I) is formed,

  • (b) cleaving off the amino protecting group X,

  • (c) optionally continuing the peptide synthesis, and

  • (d) optionally purifying the peptide product (I).



A further subject-matter of the present invention is a peptide product comprising at least one cyclic imide group of formula (I) or a salt or solvate thereof:




embedded image


  • wherein
    • R1 is a bridge (or biradical) of one or two atoms lengths,
    • R2 is an amino acid side chain,
    • * denotes an asymmetric C atom, and
    • (*) denotes an optionally asymmetric C atom.



Particularly the peptide product is a GLP-1 agonist such as an exendin peptide, more particularly lixisenatide (AVE0010).


A further subject-matter of the present invention is the use of a peptide product of formula (I) or a salt or solvate thereof as described above as a reference material for the quality control of pharmaceutical peptides, particularly of GLP-1 agonist peptides such as exendin peptides, e.g. lixisenatide.


Still, a further subject-matter of the invention is a reagent kit for determining the amount of impurities in a lixisenatide (AVE0010) product composition comprising:

    • (i) at least one stock preparation of [Asp(9)-H2O]-AVE0010 and/or
    • (ii) at least one stock preparation of [Asn(28)-NH3]-AVE0010.


Still, a further subject-matter of the present invention is a method for the quality control of a composition comprising a pharmaceutical peptide product, particularly a GLP-1 agonist peptide product, e.g. an exendin peptide product, more particularly a lixisenatide (AVE0010) product, comprising quantitatively determining the amount of a peptide product with a cyclic imide group of formula (I) or a salt or solvate thereof in said composition.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates the formation of aspartimides in AVE0010, namely on position-Asn(28)-Gly(29)- and Asp(9)-Leu(10).



FIG. 2 illustrates the formation of an aspartimide group.



FIG. 3 is an analytical chromatogram of the purified product [ASQ(9)-H2O]- AVE0010.





DETAILED DESCRIPTION OF THE DISCLOSURE

The present invention relates to a method of synthesizing a peptide product. The term “peptide product” encompasses peptides and proteins having a length of at least 5 or at least 10 amino acids and up to 50 or up to 100 amino acids or even longer. The peptide product may consist of genetically encoded amino acid building blocks or may comprise non-genetically encoded amino acid building blocks, e.g. non-naturally occurring amino acids, D-amino acids or chemically modified amino acids or may consist of several peptide chains linked e.g. by disulfide bridges. The peptide product may further contain modifications at the N- and/or C-terminus and/or at side chains, e.g. an acylation, an amidation or the addition of non-peptide side chain groups such as lipophilic groups. The peptide product may be linear or circular. Preferably, the peptide product has a length from 5-100 amino acids.


The peptide product of the invention may be in the form of a salt, e.g. a pharmaceutically acceptable salt or solvate, e.g. a hydrate. Examples of pharmaceutically acceptable salts are described in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins or in Handbook of Pharmaceutical Salts, Properties, Selection and Use, e.d. P. H. Stahl, C. G. Wermuth, 2002, jointly published by Verlag Helvetica Chimic Acta, Zurich, Switzerland, and Wiley-VCH, Weinheim, Germany. Preferably, the salt is a trifluoroacetate or acetate salt.


The peptide product comprises at least one amino acid residue capable of forming a cyclic imide group of formula (I), particularly an amino acid residue having a side chain with a carboxy or carboxyamide group such as Asp, Asn, Glu or Gln, located N-terminally to an amino acid residue with an N-atom in the peptide chain accessible for cyclisation. The C-terminally located amino acid residue may e.g. be selected from Gly, Leu, His, Asp, Arg, Phe, Ala, Cys, Gln, Glu, Lys, Met, Asn, Ser, Tyr, Thr, Ile, Trp in their D- or L-configuration and unnatural (e.g. non-genetically encoded) amino acids, which are e.g. listed in supplier's catalogues.


Preferably, the peptide product which has been synthesized according to the present invention comprises at least one cyclic imide group of formula (I) and at least one amino acid residue having a side chain with a carboxy or carboxamide group such as Asp, Asn, Glu or Gln, which is not present as cyclic imide group.


The synthesis of the peptide product is carried out by chemical synthesis procedures, particularly by a solid phase synthesis procedure which is well-known in the art, e.g. a procedure involving a stepwise coupling of synthesis building blocks to a peptide chain bound to a carrier, e.g. a synthetic resin. In a preferred embodiment of the invention, the peptide product is a GLP-1 agonist peptide, such as an an exendin peptide, e.g. exendin-4, liraglutide or lixisenatide (AVE0010) or GLP-1 receptor agonist like GLP-1 or -2, oxyntomodulin, glucagon or peptides which bind and activate both the glucagon and the GLP-1 receptor (Hjort et al., Journal of Biological Chemistry, 269, 30121-30124, 1994; Day J W et al., Nature Chem. Biol. 5:749-757, 2009) and suppress body weight gain and reduce food intake which are described in patent applications WO 2008/071972, WO 2008/101017, WO 2009/155258, WO 2010/096052, WO 2010/096142, WO 2011/075393, WO 2008/152403, WO 2010/070251, WO 2010/070252, WO 2010/070253, WO 2010/070255, WO 2011/160630, WO 2011/006497, WO 2011/152181, WO 2011/152182, WO 2011/117415, WO 2011/117416, the contents of which are herein incorporated by reference, or GIP and peptides which bind and activate both the GIP and the GLP-1 receptor and optionally the glucagon receptor, and improve glycemic control, suppress body weight gain and reduce food intake as described in patent applications WO 2011/119657, WO 2012/138941, WO 2010/011439, WO 2010/148089, WO 2011/094337, and WO 2012/088116, the contents of which are herein incorporated by reference. Further examples of peptide products are insulins and insulin analogues or DPP-4 inhibitors. More preferably, the peptide product is an exendin peptide, most preferably lixisenatide (AVE0010).


Step (a) of the method of the invention comprises coupling a synthesis acid building block of formula (II) to a peptide product of formula (III). The building block (II) comprises a group Z, wherein Z is a carboxy group capable of coupling to an amino group under coupling conditions, i.e. in the presence of coupling reagents in an organic solvent. Further, the amino acid building block (II) comprises a side chain R1Y, wherein R1 is a biradical or bridge having a length of one to two atoms, preferably a C1-C2 group, more preferably a —CH2— or a —CH2—CH2— group. Y is an unprotected carboxy or carboxamido group. Building block (II) also has a protected amino group NHX, wherein X is an amino protecting group, e.g. a fluorenylmethoxycarbonyl (Fmoc) group or another base-labile protecting group or an acid-labile protecting group such as butoxycarbonyl (Boc), trityl (Trt) or a protecting group selected from carboxybenzyl (Cbz), allyloxycarbonyl (Alloc) or another protecting group for amino groups mentioned in Green's Protective Groups in Organic Synthesis, John Wiley & Sons, 4th ed. 2006, chapter 7, Protection for the Amino Group, mentioned in Protecting Groups, P. J. Kocierski, Thieme, 3rd ed. 2005, chapter 8, Amino Protecting Groups or mentioned in Houben-Weyl, Methods in Organic Chemistry, Synthesis of Peptides and Peptidomimetics, 4th ed. 2001, chapter 2, Protection of Functional groups, the contents of which are herein incorporated by references. Building block (II) further has an asymmetric carbon atom denoted by *. Preferably, the asymmetric carbon atom is in the L-configuration.


Peptide product (III), which may be an intermediate product of peptide synthesis, has a free amino group capable of reacting with group Z of synthesis building block (II) under coupling conditions, i.e. in the presence of coupling reagents in an organic solvent. The intermediate peptide product comprises an N-terminal amino acid building block with an optionally protected amino acid side chain R2′ and a peptidic residue R3 constituted of one or more amino acids. The peptidic residue is preferably bound to a solid phase carrier, e.g. a resin suitable for peptide synthesis. Peptide product (III) may also contain an asymmetric carbon atom denoted as (*) when R2′ is different from H. Preferably, the asymmetric carbon atom is in the L-configuration.


The coupling conditions in step (a) preferably comprise a reaction time of at least 4 h, 8 h, 12 h, 16 h or 24 h and up to 48 h, 72 h or 96 h. Further, the coupling conditions preferably comprise a reaction temperature between 0 and 50° C., preferably between 15 and 40° C. The coupling reaction is carried out in the presence of a coupling reagent such as TBTU (O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate, HBTU (2-(1H-benzotrialzole-1-yl),1,1,3,3-tetramethyluronium) hexafluorophosphate or HOBt (1-hydroxybenzotriazole)/DIC (diisopropylcarbodiimide) and an organic base such as DIPEA (diisopropylethylamine) in a suitable organic solvent such as DMF (dimethylformamide), or other coupling reagents. For example, coupling reagents named in A. El-Faham, F. Albericio, Chem. Rev. 2011, 111, 6557-6602, can be employed, the content of which is herein incorporated.


Preferably, the coupling step is carried out under conditions wherein the yield of the cyclic imide product is ≥50%, ≥60%, ≥70%, ≥80% or ≥90% based on the amount of the total yield in coupling step (a), i.e. the amount of amino acid building block (II) coupled to the peptide intermediate product (III).


Step (b) of the inventive method comprises cleaving off the amino protecting group X after the coupling step in the presence of a deprotecting agent such as DBU (1,8-diazabicyclo[5.4.0]undec-7-ene). Further suitable deprotecting agents are mentioned in Green's Protective Groups in Organic Synthesis, John Wiley & Sons, 4th ed. 2006, chapter 7, Protection for the Amino Group, mentioned in Protecting Groups, P. J. Kocierski, Thieme, 3rd ed. 2005, chapter 8, Amino Protecting Groups or mentioned in Houben-Weyl, Methods in Organic Chemistry, Synthesis of Peptides and Peptidomimetics, 4th ed. 2001, chapter 2, Protection of Functional groups, the contents of which are herein incorporated by references. The use of piperidine as a deprotecting agent is less recommended since it results in a ring opening of the cyclic imide group.


Optional Step (c) comprises continuing the synthesis of the peptide product after formation of the cyclic imide group. The synthesis may be continued under standard conditions except that the use of piperidine, as a deprotecting reagent should be avoided. Step (c) may also comprise deprotecting side chain protected amino acid groups and cleaving the peptide off from the solid phase carrier. These procedures may be carried out under standard conditions as known in the art.


Optional step (d) comprises purifying the peptide product (I) from other peptides obtained in the peptide synthesis procedure. Preferably, the purification involves a chromatographic procedure. The term “chromatographic procedure” involves a chromatographic procedure suitably for the purification of peptide products, including e.g. ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, size exclusion chromatography, and particularly high performance liquid chromatography (HPLC) and more particularly Reverse Phase HPLC, or combinations of several procedures. More preferably, the chromatographic procedure involves at least one Reverse Phase HPLC chromatography step.


As a result of the inventive synthesis method, an isolated and purified peptide product comprising a cyclic imide group of formula (I) may be obtained. Preferably, this peptide product is substantially free from degradation products, e.g. deamidation products, racemised products and/or isoasparagine-containing products. Preferably, the amount of degradation products is less than 1%, 0.5% or 0.1% based on the amount of the total product as measured by means of chromatoghraphy, e.g. HPLC.


The peptide product comprises at least one cyclic imide group, e.g. 1, 2 or 3 cyclic imide groups. Preferably, the peptide product comprises one or two cyclic imide groups. More preferably, the peptide product comprises one or more uncyclisized cyclic imide groups.


The peptide product is preferably a therapeutic peptide, e.g. an exendin peptide, particularly lixisenatide (AVE0010) having at least one cyclic imide group. Specific examples of preferred peptide products are [Asp(9)-H2O]-AVE0010, [Asn(28)-NH3]-AVE0010, [Asp(9)-H2O]-Exendin-4, [Asn(28)-NH3]-Exendin-4, [Asp(9)-H2O]-Liraglutide, [Asp(16)-H2O]-GLP-1(7-36), [Asp(9)-H2O]-Glucagon, [Asp(15)-H2O]-Glucagon, [Asp(21)-H2O]-Glucagon, [Asn(28)-NH3]-Glucagon, [Asp(9)-H2O]-Oxyntomodulin, [Asp(15)-H2O]-Oxyntomodulin, [Asp(21)-H2O]-Oxyntomodulin, [Asn(28)-NH3]-Oxyntomodulin, [Asn(32)-N H3]-Oxyntomodulin, [Asn(34)-NH3]-Oxyntomodulin, [Asn(35)-NH3]-Oxyntomodulin and all peptides with the motif -Asn-X- and -Asp-X- which bind and activate both the glucagon and the GLP-1 receptor (Hjort et al., Journal of Biological Chemistry, 269, 30121-30124, 1994; Day J W et al., Nature Chem Biol, 5:749-757, 2009) and suppress body weight gain and reduce food intake which are described in patent applications WO 2008/071972, WO 2008/101017, WO 2009/155258, WO 2010/096052, WO 2010/096142, WO 2011/075393, WO 2008/152403, WO 2010/070251, WO 2010/070252, WO 2010/070253, WO 2010/070255, WO 2011/160630, WO 2011/006497, WO 2011/152181, WO 2011/152182, WO 2011/117415, WO 2011/117416, the contents of which are herein incorporated by reference, or GIP and peptides which bind and activate both the GIP and the GLP-1 receptor and optionally the glucagon receptor, and improve glycemic control, suppress body weight gain and reduce food intake as described in patent applications WO 2011/119657, WO 2012/138941, WO 2010/011439, WO 2010/148089, WO 2011/094337, and WO 2012/088116, the contents of which are herein incorporated by reference.


The peptide product of the invention may be used as a reference material, e.g. for the quality control of pharmaceutical peptides, particularly for use in a quality control method wherein the amount of undesired cyclic imide group containing by-products in a peptide product preparation is quantitatively determined.


Quantitative determination of by-products in a peptide product sample preferably involves mass spectrometry. In addition to mass spectrometry, the determination may involve a prior chromatographic procedure, e.g. in order to separate other impurities from the peptide product or from other ingredients of the composition. Preferably, mass spectrometry is combined with HPLC.


Mass spectrometry is based on a measurement of the mass-to-charge ratio of charged particles. In a typical mass spectrometry procedure, the sample is loaded onto the mass spectrometry instrument and volatilized. The sample components are ionized and the resulting ions are separated in the mass analyzer by electromagnetic fields. The resulting ions are detected and the signal is processed into a mass spectrum. For the ionization of peptide products, electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) may be used. The resulting ions may be detected by highly sensitive methods such as Orbitrap or Fourier Transform (FT)-Ion Cyclotron Resonance (ICR) detection systems.


By means of mass spectrometry, a peak derived from a cyclic imide group containing by-product may be identified, which differs from the mass of the non-cyclisized product by 18 (mass of H2O) or 17 (mass of NH3).


Further, the present invention shall be explained in more detail by the following examples describing synthesis, chromatographic purification and analytic characterization of the cyclic imide group containing peptide [Asp(9)-H2O]-AVE0010.


EXAMPLES
1. Synthesis of [Asp(9)-H2O]-AVE0010

[Asp(9)-H2O]-AVE0010 is a by-product in the synthesis of the pharmaceutical peptide product AVE0010. It is generated when the side chain of amino acid Asp(9) forms an aspartimide with the N-atom of the adjacent amino acid Leu(10) under removal of water.


The amino acid sequence of [Asp(9)-H2O]-AVE0010 is as follows:









H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-X-Ser-Lys-Gln-





Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-





Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-





Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2








embedded image


Peptide synthesis was carried out with the peptide synthesizer Bio536 (CS Bio). As a starting material, N-terminally Fmoc protected (20-44)-AVE0010 resin was used. The starting material was prepared by peptide synthesis under standard conditions.


25.56 g Fmoc-(20-44)-AVE0010 resin were mixed with 250 ml DMF, stirred for 5 minutes and then swollen for 2 hours. DMF was then aspirated through a frit. After the swelling, Fmoc cleavage was carried out with 25% piperidine in DMF.


Then, amino acids Val(19) to Leu(10) were coupled to the starting material under standard conditions using amino acid derivatives with a Fmoc protected amino group and a protected side chain, e.g. an O-t-butyl (OtBu) protected Glu side chain, a trityl(Trt)-protected Gln side chain, a butyloxycarbonyl(Boc)-protected Lys side chain and a t-butyl(tBu)-protected Ser side chain.


Then, a Fmoc-Asp-OH building block (without side chain protection group) was coupled under conditions favouring the formation of an aspartimide group.


4.26 g Fmoc-Asp-OH, 1.9 g HOBT hydrate and 2 mL DIC in 250 mL DMF were mixed with the resin. The reaction mixture was stirred overnight. The coupling solution was then pumped out and the resin was washed twice with DMF. Then, 3 eq HOBT and 3 eq DIC in DMF were mixed with the resin. The resin was stirred over the weekend.


To determine the degree of aspartimide formation, a resin sample was treated with a cleavage mixture called King's Cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266) to liberate the aspartimide containing peptide from the resin. By means of mass-spectrometric measurements, it was found that the coupling product was mainly present in form of a cyclic aspartimide.


Subsequently, a solution of 2% of DBU in DMF was used for the Fmoc cleavage.


Finally, amino acids Ser(8) to Gly(1) were coupled under standard conditions except that the Fmoc protection group was not cleaved with piperidine but with DBU, in order to prevent an opening of the cyclic aspartimide group. As a result, 30.5 g [Asp(9)-H2O]-AVE0010 on resin were obtained.


The cleavage of peptide from resin and the side chain protection group was carried out with King's Cocktail. 9.25 g raw product (purity of 23.4% as measured by UV at 215 nm) resulted from 30.5 g Fmoc protected resin after the solid phase synthesis.


The cleavage of the peptide from the resin was carried out under standard conditions (King et al., 1990, Supra). In total, 9.25 g of crude [Asp(9)-H2O]-AVE0010 were obtained after drying under vacuum.


2. Chromatographic Purification of [Asp(9)-H2O]-AVE0010

Purification was carried out by two RP-HPLC steps and subsequent freeze drying. The RP-HPLC steps were conducted with a Varian PrepStar device. Stainless steel columns packed with C18 reverse phase material (e.g. Daisogel C18 for the first step or Hydrospher C18 for the second step) were used as stationary phase. H2O+0.1% trifluoroacetic acid were used as mobile phase A and acetonitrile as mobile phase B. The gradient was carried out at 0-80% mobile phase B (Daisogel) and 0-35% mobile phase B (Hydrospher), respectively.


As a result, 540 mg [Asp(9)-H2O]-AVE0010 with a purity of 91.50% (area ° as measured by HPLC) were obtained. An analytical chromatogram of the purified product is shown in FIG. 3.


3. Analytic Characterization

The purified product was characterized mass spectrometrically. Purified AVE0010 was used as a reference standard.


This analytic characterization showed the correct product [Asp(9)-H2O]-AVE0010 with a molecular weight (M+H)+=4838.460, and the AVE0010 standard of 4856.544. The mass difference of [Asp(9)-H2O]-AVE0010 to AVE0010 is 18.084 which equals to an H2O molecule. The theoretical monoisotopic molecular weight of [Asp(9)-H2O]-AVE0010 is 4837.534.

Claims
  • 1. A method of synthesizing a peptide product comprising at least one cyclic imide group of formula (I) or a salt or solvate thereof:
  • 2. The method of claim 1, wherein R1 is —CH2—.
  • 3. The method of claim 1, wherein R1 is —CH2—CH2—.
  • 4. The method of claim 1, wherein Y is a carboxy group.
  • 5. The method of claim 1, wherein Y is a carboxamido group.
  • 6. The method of claim 1, wherein X is an Fmoc amino protecting group.
  • 7. The method of claim 1, wherein the solid phase carrier is a resin.
  • 8. The method of claim 1, wherein the coupling conditions in step (a) comprise a reaction time of at least 12 h, a temperature of between 15 and 40° C.
  • 9. The method of claim 1, wherein the coupling conditions in step (a) comprise dimethylformamide (DMF) as organic solvent.
  • 10. The method of claim 1, wherein the yield of a cyclic imide product in coupling step (a) is >50% based on the amount of the total yield of a coupling product in step (a).
  • 11. The method of claim 1, wherein cleaving step (b) is carried out with a deprotecting agent selected from 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
  • 12. The method of claim 1, wherein the cyclic imide group of formula (I) is selectively introduced at least one predetermined position of the peptide product.
  • 13. The method of claim 8, further comprising repeated addition of coupling reagents, wherein the coupling agents are selected from O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), (2-(1H-benzotriazole-1-yl),1,1,3,3-tetramethyluronium) hexafluorophosphate (HBTU) with diisopropylethylamine (DIPEA), and 1-hydroxybenzotriazole/diisopropylcarbodiimide (HOBt/DIC).
  • 14. The method of claim 1, wherein the least one cyclic imide group of formula (I) is at position Asp(9) of the peptide product.
  • 15. The method of claim 1, wherein the peptide product comprising at least one cyclic imide group of formula (I) is lixisenatide having at least one cyclic imide group at position Asp(9).
  • 16. The method of claim 1, wherein the peptide product comprising at least one cyclic imide group of formula (I) is selected from [Asp(9)-H2O]-lixisenatide, [Asp(9)-H2O]-exendin-4, [Asp(9)-H2O]-liraglutide, and a salt or solvate thereof.
  • 17. The method of claim 1, wherein the least one cyclic imide group of formula (I) is at position Asp(9), Asp(16), Asp(15), Asp(21), Asn(32), or Asn(35) of the peptide product.
  • 18. The method of claim 1, wherein the peptide product comprising at least one cyclic imide group of formula (I) is selected from [Asp(9)-H2O]-lixisenatide, [Asp(9)-H2O]-exendin-4, [Asp(9)-H2O]-liraglutide, [Asp(16)-H2O]-GLP-1(7-36), [Asp(9)-H2O]-glucagon, [Asp(15)-H2O]-glucagon, [Asp(21)-H2O]-glucagon, [Asp(9)-H2O]-oxyntomodulin, [Asp(15)-H2O]-oxyntomodulin, [Asp(21)-H2O]-oxyntomodulin, [Asn(32)-NH3]-oxyntomodulin, [Asn(34)-NH3]-oxyntomodulin, [Asn(35)-NH3]-oxyntomodulin, and a salt or solvate thereof.
Priority Claims (1)
Number Date Country Kind
13160380 Mar 2013 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2014/055511 3/19/2014 WO 00
Publishing Document Publishing Date Country Kind
WO2014/147129 9/25/2014 WO A
US Referenced Citations (157)
Number Name Date Kind
3835175 Carpino et al. Sep 1974 A
3906031 Carpino et al. Sep 1975 A
4108846 Carpino et al. Aug 1978 A
4755591 Koenig et al. Jul 1988 A
5169932 Hoeger et al. Dec 1992 A
5175254 Bernard et al. Dec 1992 A
5247067 Terukatsu et al. Sep 1993 A
5296468 Hoeger et al. Mar 1994 A
5352796 Hoeger et al. Oct 1994 A
5460786 Nokihara Oct 1995 A
5478810 Stueber et al. Dec 1995 A
5502165 Ho et al. Mar 1996 A
5503805 Sugarman et al. Apr 1996 A
5516891 Siwruk et al. May 1996 A
5536816 Hohler et al. Jul 1996 A
5563032 Fields et al. Oct 1996 A
5565574 Hoeger et al. Oct 1996 A
5576296 Bartfai et al. Nov 1996 A
5580957 Hoeger et al. Dec 1996 A
5602230 Heavner et al. Feb 1997 A
5602231 Cotton et al. Feb 1997 A
5607858 Stueber et al. Mar 1997 A
5614608 Krchnak et al. Mar 1997 A
5618785 Heavner et al. Apr 1997 A
5639603 Sugarman et al. Jun 1997 A
5665975 Sugarman et al. Sep 1997 A
5708153 Dower et al. Jan 1998 A
5710123 Heavner et al. Jan 1998 A
5710249 Hoeger et al. Jan 1998 A
5736315 Fields et al. Apr 1998 A
5744450 Hoeger et al. Apr 1998 A
5750649 Hohler et al. May 1998 A
5770358 Dower et al. Jun 1998 A
5773575 Ho et al. Jun 1998 A
5789162 Dower et al. Aug 1998 A
5830637 Frank et al. Nov 1998 A
5891640 Frank et al. Apr 1999 A
5916876 Heavner et al. Jun 1999 A
6022685 Fields et al. Feb 2000 A
6028168 Goodman et al. Feb 2000 A
6040423 Frank et al. Mar 2000 A
6056926 Sugarman et al. May 2000 A
6111065 Heavner et al. Aug 2000 A
6136781 Kitada et al. Oct 2000 A
6140493 Dower et al. Oct 2000 A
6143497 Dower et al. Nov 2000 A
6165717 Dower et al. Dec 2000 A
6165730 De Leys Dec 2000 A
6165778 Kedar et al. Dec 2000 A
6210903 De Leys Apr 2001 B1
6268339 De Leys Jul 2001 B1
6416949 Dower et al. Jul 2002 B1
6469136 Bray et al. Oct 2002 B1
6476186 Hsieh et al. Nov 2002 B1
6492460 Haq et al. Dec 2002 B2
6617307 Nishimura et al. Sep 2003 B1
6649735 De Leys Nov 2003 B1
6667387 De Leys Dec 2003 B1
6673769 Goodman et al. Jan 2004 B2
6703480 Balu Mar 2004 B1
6709828 De Leys Mar 2004 B1
6747125 Hoeger et al. Jun 2004 B1
6767993 Bray et al. Jul 2004 B2
6809190 Ikeda et al. Oct 2004 B2
6849710 Arzeno Feb 2005 B1
7009037 Sorensen Mar 2006 B2
7049293 Nishimura et al. May 2006 B2
7138489 Nishimura et al. Nov 2006 B2
7176282 Holm et al. Feb 2007 B1
7183430 Montiel et al. Feb 2007 B2
7235242 Achtman et al. Jun 2007 B2
7329646 Sun et al. Feb 2008 B2
7348404 Holm et al. Mar 2008 B2
7393920 Collins et al. Jul 2008 B2
7402663 Collins et al. Jul 2008 B2
7414106 Camarero et al. Aug 2008 B2
7414107 Larsen et al. Aug 2008 B2
7417028 Ewing et al. Aug 2008 B2
7425541 Dubois et al. Sep 2008 B2
7439222 Guinn et al. Oct 2008 B2
7459522 Balu Dec 2008 B2
7507791 Skripko Mar 2009 B2
7534763 Qian et al. May 2009 B2
7550560 Collins et al. Jun 2009 B2
7563865 Collins et al. Jul 2009 B2
7582728 Collins et al. Sep 2009 B2
7598222 Prouty et al. Oct 2009 B2
7612168 Sorensen Nov 2009 B2
7691968 Evans et al. Apr 2010 B2
7745570 Tomich et al. Jun 2010 B2
7834142 Li Nov 2010 B2
7902488 Collins et al. Mar 2011 B2
7935786 Larsen May 2011 B2
7939628 Collins et al. May 2011 B2
7960349 Ewing et al. Jun 2011 B2
7960506 Nash Jun 2011 B2
7981998 Nash Jul 2011 B2
8034787 Dubois Oct 2011 B2
8058393 Collins et al. Nov 2011 B2
8058394 Kajihara et al. Nov 2011 B2
8097586 Lv et al. Jan 2012 B2
8114959 Juul-Mortensen Feb 2012 B2
8153761 Collins et al. Apr 2012 B2
8178474 Melnyk et al. May 2012 B1
8202837 Bush et al. Jun 2012 B2
8227571 Chen et al. Jul 2012 B2
8252896 Hsiao et al. Aug 2012 B2
8426560 Collins et al. Apr 2013 B2
8435800 Gengrinovitch May 2013 B2
8609809 Nash Dec 2013 B2
8620595 Krokhin et al. Dec 2013 B2
8710011 Garcia et al. Apr 2014 B2
8716221 Lv et al. May 2014 B2
8802819 Fernando et al. Aug 2014 B2
8846862 Collins et al. Sep 2014 B2
8933196 Chen et al. Jan 2015 B2
8946166 Garcia et al. Feb 2015 B2
8993716 Carreno et al. Mar 2015 B2
9175056 Nash Nov 2015 B2
9206223 Nash et al. Dec 2015 B2
9211522 Collins et al. Dec 2015 B2
9260474 Pan et al. Feb 2016 B2
9263194 Seo et al. Feb 2016 B2
9266921 Garcia et al. Feb 2016 B2
9290537 Madded et al. Mar 2016 B2
9314521 Ossendorp et al. Apr 2016 B2
9315564 Serraima et al. Apr 2016 B2
9364772 Larsen et al. Jun 2016 B2
9393186 Alminana et al. Jul 2016 B2
9394336 Nash et al. Jul 2016 B2
9394341 Wen et al. Jul 2016 B2
9422330 Wu et al. Aug 2016 B2
9605344 Jiang et al. Mar 2017 B2
9724622 Anwer Aug 2017 B2
9766217 Kidal et al. Sep 2017 B2
20020058788 Sheppeck May 2002 A1
20030191049 Amblard Oct 2003 A1
20040086949 Holm May 2004 A1
20040235049 Melnyk et al. Nov 2004 A1
20060079667 Skripko Apr 2006 A1
20060167224 Tonosaki et al. Jul 2006 A1
20070129537 Camarero et al. Jun 2007 A1
20090111152 Sherman Apr 2009 A1
20090197315 Barron Aug 2009 A1
20100021510 Carreno et al. Jan 2010 A1
20100056755 Hsiao et al. Mar 2010 A1
20100292436 Bai et al. Nov 2010 A1
20110245461 Krokhin et al. Oct 2011 A1
20110313131 Christelle et al. Dec 2011 A1
20110319594 Bai et al. Dec 2011 A1
20120296068 Chen et al. Nov 2012 A1
20130289241 Bai et al. Oct 2013 A1
20140187745 Wen et al. Jul 2014 A1
20150051372 Qin et al. Feb 2015 A1
20150073122 Seo et al. Mar 2015 A1
20150232527 Gong et al. Aug 2015 A1
20150274799 Gong et al. Oct 2015 A1
Foreign Referenced Citations (173)
Number Date Country
2104099 Aug 1993 CA
2050216 Mar 2003 CA
2765196 Dec 2004 CA
2458084 Sep 2005 CA
2915484 Jun 2016 CA
1699404 Nov 2005 CN
101255191 Sep 2008 CN
101357937 Feb 2009 CN
101357938 Feb 2009 CN
101463078 Jun 2009 CN
101463081 Jun 2009 CN
101525368 Sep 2009 CN
101525370 Sep 2009 CN
101538324 Sep 2009 CN
102174082 Sep 2011 CN
102558338 Jul 2012 CN
102875663 Jan 2013 CN
103242443 Aug 2013 CN
103333237 Oct 2013 CN
103536912 Jan 2014 CN
103613655 Mar 2014 CN
103965285 Aug 2014 CN
104086631 Oct 2014 CN
102411801 Dec 2014 CN
105111303 Dec 2015 CN
105585612 May 2016 CN
4244565 Jul 1994 DE
4341471 Jun 1995 DE
19543628 May 1997 DE
0402313 Dec 1990 EP
0445801 Sep 1991 EP
0450715 Oct 1991 EP
1445260 Aug 2004 EP
1923397 May 2008 EP
20065208 Mar 2006 FI
2864830 Jul 2005 FR
200105069 Apr 2001 GB
200210185 Jun 2002 GB
200613147 Aug 2006 GB
WO 9106543 May 1991 WO
WO 9217025 Oct 1992 WO
WO 9220709 Nov 1992 WO
WO 9303056 Feb 1993 WO
WO 9306121 Apr 1993 WO
WO 9318054 Sep 1993 WO
WO 9324526 Dec 1993 WO
WO 9325571 Dec 1993 WO
WO 9404568 Mar 1994 WO
WO 9405314 Mar 1994 WO
WO 9409032 Apr 1994 WO
WO 9414836 Jul 1994 WO
WO 9500474 Jan 1995 WO
WO 9508561 Mar 1995 WO
WO 9512608 May 1995 WO
WO 9514787 Jun 1995 WO
WO 9521858 Aug 1995 WO
WO 9527727 Oct 1995 WO
WO 9622157 Jul 1996 WO
WO 9634012 Oct 1996 WO
WO 9640759 Dec 1996 WO
WO 9711372 Mar 1997 WO
WO 9811125 Mar 1998 WO
WO 9811126 Mar 1998 WO
WO 9831791 Jul 1998 WO
WO 9946283 Sep 1999 WO
WO 0033888 Jun 2000 WO
WO 0134635 May 2001 WO
WO 0138342 May 2001 WO
WO 0155213 Aug 2001 WO
WO 0195945 Dec 2001 WO
WO 0220554 Mar 2002 WO
WO 0240512 May 2002 WO
WO 02053606 Jul 2002 WO
WO 02070546 Sep 2002 WO
WO 02074782 Sep 2002 WO
WO 02083606 Oct 2002 WO
WO 03018605 Mar 2003 WO
WO 03093301 Nov 2003 WO
WO 03093302 Nov 2003 WO
WO 03095475 Nov 2003 WO
WO 2004018502 Mar 2004 WO
WO 2004022578 Mar 2004 WO
2004035623 Apr 2004 WO
WO 2004035623 Apr 2004 WO
WO 2004089504 Oct 2004 WO
WO 2004105685 Dec 2004 WO
WO 2004105790 Dec 2004 WO
WO 2005019262 Mar 2005 WO
WO 2005063791 Jul 2005 WO
WO 2005080424 Sep 2005 WO
WO 2005087794 Sep 2005 WO
WO 2006008050 Jan 2006 WO
WO 2006014287 Feb 2006 WO
WO 2006040037 Apr 2006 WO
WO 2006054310 May 2006 WO
WO 2006108594 Oct 2006 WO
WO 2006117227 Nov 2006 WO
WO 2006127048 Nov 2006 WO
WO 2006127948 Nov 2006 WO
WO 2007033383 Mar 2007 WO
WO 2007056681 May 2007 WO
WO 2007065691 Jun 2007 WO
WO 2007113356 Oct 2007 WO
WO 2007113386 Oct 2007 WO
WO 2007139589 Dec 2007 WO
WO 2007140284 Dec 2007 WO
WO 2008001109 Jan 2008 WO
WO 2008028974 Mar 2008 WO
WO 2008044890 Apr 2008 WO
2008071972 Jun 2008 WO
WO 2008076904 Jun 2008 WO
2008101017 Aug 2008 WO
WO 2008109079 Sep 2008 WO
WO 2008137165 Nov 2008 WO
2008152403 Dec 2008 WO
WO 2009003666 Jan 2009 WO
WO 2009074483 Jun 2009 WO
WO 2009098707 Aug 2009 WO
WO 2009106343 Sep 2009 WO
WO 2009132231 Oct 2009 WO
WO 2009138488 Nov 2009 WO
2009155258 Dec 2009 WO
2010011439 Jan 2010 WO
WO 2010009872 Jan 2010 WO
WO 2010028122 Mar 2010 WO
WO 2010028131 Mar 2010 WO
WO 2010033254 Mar 2010 WO
WO 2010034032 Mar 2010 WO
WO 2011107447 Mar 2010 WO
2010070251 Jun 2010 WO
2010070252 Jun 2010 WO
2010070253 Jun 2010 WO
2010070255 Jun 2010 WO
WO 2010063122 Jun 2010 WO
WO 2010063123 Jun 2010 WO
WO 2010063124 Jun 2010 WO
2010096052 Aug 2010 WO
2010096142 Aug 2010 WO
WO 2010091893 Aug 2010 WO
WO 2010118880 Oct 2010 WO
2010148089 Dec 2010 WO
2011006497 Jan 2011 WO
WO 2011009626 Jan 2011 WO
WO 2011047868 Apr 2011 WO
2011075393 Jun 2011 WO
2011094337 Aug 2011 WO
2011117416 Sep 2011 WO
2011119657 Sep 2011 WO
2011117415 Dec 2011 WO
2011160630 Dec 2011 WO
WO 2011161007 Dec 2011 WO
WO 2012055509 May 2012 WO
WO 2012057624 May 2012 WO
2012088116 Jun 2012 WO
WO 2012085279 Jun 2012 WO
2012138941 Oct 2012 WO
WO 2012130775 Oct 2012 WO
WO 2012155780 Nov 2012 WO
WO 2012161654 Nov 2012 WO
WO 2013051936 Apr 2013 WO
WO 2013093639 Jun 2013 WO
WO 2013156493 Oct 2013 WO
WO 2013170963 Nov 2013 WO
WO 2014118797 Aug 2014 WO
WO 2015009701 Jan 2015 WO
WO 2015038919 Mar 2015 WO
WO 2015078477 Jun 2015 WO
WO 2015128687 Sep 2015 WO
WO 2016020349 Feb 2016 WO
WO 2016057683 Apr 2016 WO
WO 2016067271 May 2016 WO
WO 2016084100 Jun 2016 WO
WO 2017162653 Sep 2017 WO
Non-Patent Literature Citations (26)
Entry
Larsen and Holm, Journal of Peptide Research (1998) 52, 470.
Louis A. Carpino. The 9-Fluorenylmethyloxycarbonyl Family of Base-Sensitive Amino-Protecting Groups. Acc. Chem. Res. 1987, 20, 401-407. (Year: 1987).
Fields et al. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. Mar. 1990;35(3):161-214. (Year: 1990).
Anonymous: Lixisenatide—Wikipedia, the free encyclopedia, Feb. 24, 2013, pp. 1-4, XP055120784, Retrieved from internet: URL: http://en.wikipedia.org/w/index. php?title= Lixisenatide&olidid=540119995 (retrieved on May 28, 2014).
Alvarez-Gutierrez et al., “Solid phase synthesis of 1,3-disubstituted succinimides”, Tetrahedron Letters, 41(5): 609-612 (2000).
Aswad et al., “Isoaspartate in peptides and proteins: formation, significance, and analysis”, Journal of Pharmaceutical and Biomedical Analysis, 21: 1129-1136 (2000).
Cebrian et al., “Synthesis of peptide sequences related to thrombospondin: factors affecting aspartimide by-product formation”, J. Peptide Res., 62: 238-244 (2003).
Day et al., “A new glucagon and GLP-1 co-agonist eliminates obesity in rodents”, Nature Chemical Biology, 5(10): 749-57 (2009).
De Boni et al., “Analysis of asparyl peptide degradation products by high-performance liquid chromatography and high-performance liquid chromatography-mass spectrometry”, Journal of Chromatography A, 1022: 95-102 (2004).
El-Faham et al., “Peptide coupling reagents, more than a letter soup”, Chem. Rev., 111: 6557-6602 (2011).
Flaih et al., “A one-step synthesis of aminosuccinyl peptides”, Synlett, 6: 896-898 (2000).
Geiger et al., “Deamidation, isomerization, and racemization at asparaginyl and aspartyl residue in peptides”, Journal of Biological Chemistry, 262(2): 785-794 (1987).
Hekman et al., “Isolation and identification of cyclic imide and deamidation products in heat stressed pramlinitide injection drug product”, Journal of Pharmaceutical and Biomedical Analysis, 20: 763-772 (1999).
Hjorth et al., “Glucagon and glucagon-like peptide 1: Selective receptor recognition via distinct peptides epitopes”, The Journal of Biological Chemistry, 269(48): 30121-30124 (1994).
Houchin et al., “Deamidation, acylation and proteolysis of a model peptide in PLGA films”, Journal of Controlled Release, 112: 111-119 (2006).
King et al., “A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis”, Int. Peptide Protein Res., 36: 255-266 (1990).
Linder et al., “Age-dependent deamidation of asparagine residues in proteins”, Experimental Gerontology, 36: 1551-1563 (2001).
Mergler et al., “The aspartimide problem in Fmoc-based SSPS. Part II”, Journal of Peptide Science, 9: 36-46 (2003).
Mergler et al., “The aspartimide problem in Fmoc-based SSPS. Part II”, Journal of Peptide Science, 9: 518-526 (2003).
Mergler et al., “The aspartimide problem in Fmoc-based SSPS. Part III”, Journal of Peptide Science, 11: 650-657 (2005).
Ritz-Timme et al., “Racemization of aspartic acid in human proteins”, Ageing Research Reviews, 12: 43-59 (2002).
Subiros-Funosas et al., “Aspartimide formation in peptide chemistry: occurrence, prevention strategies and the role of hydroxylamines”, Tetrahedron, 67(45): 8595-8606 (2011).
Vintner at al., “Synthesis of stereoisomers and isoforms of a tryptic heptapeptide fragment of human growth hormone and analysis by reverse-phase HPLC and capillary electrophoresis”, European Journal of Biochemistry, 235 (1-2): 304-309 (1996).
Extended European Search Report issued in European Application No. 13160380.5 (dated Jul. 9, 2013).
International Search Report and Written Opinion issued in International Patent Application No. PCT/EP2014/055511 (dated Jun. 17, 2014).
International Preliminary Report on Patentability (Chapter II) issued in International Patent Application No. PCT/EP2014/055511 (dated Apr. 13, 2015).
Related Publications (1)
Number Date Country
20160289263 A1 Oct 2016 US